What is the recommended approach to treating cancer in a patient receiving chronic dialysis?

Treating Cancer in Dialysis Patients

Cancer treatment is feasible and should be pursued in dialysis patients using the same therapeutic intent as in patients with normal renal function, but requires careful dose adjustment for renally eliminated drugs (approximately 57% of anticancer agents) and strategic timing of chemotherapy administration relative to dialysis sessions. 1, 2, 3

Core Management Principles

Multidisciplinary Coordination

• Establish coordinated care between oncology, nephrology, and pharmacy teams before initiating any cancer treatment to optimize drug delivery, dosing adjustments, and dialysis scheduling. 1, 2, 3
• This collaboration is essential because pharmacokinetic modifications in end-stage renal disease (ESRD) create unique challenges that require expertise from all three specialties. 2

Two Critical Pharmacokinetic Considerations

1. Dose Adjustment for Renal Impairment

• Approximately 57% of anticancer drugs require dosage reduction in dialysis patients to prevent drug accumulation and severe toxicity. 1
• Use the CKD-EPI equation to guide chemotherapy dosing decisions, as recommended by KDIGO for oncology patients with chronic kidney disease. 4
• Failing to adjust doses appropriately leads to significantly higher rates of cytopenia and diarrhea while paradoxically reducing drug efficacy. 4

2. Timing Relative to Dialysis Sessions

• Administer 64% of anticancer drugs immediately after dialysis sessions to prevent premature drug removal during dialysis, which would result in loss of therapeutic efficacy. 1, 5
• For drugs with significant dialysis clearance, dosage increases may be required to maintain adequate therapeutic levels. 6

Specific Drug Classes and Dosing Strategies

Tyrosine Kinase Inhibitors (TKIs) in Dialysis Patients

• TKIs can be safely used in dialysis patients, including those with metastatic renal cell carcinoma, without requiring increased dialysis frequency. 4
• Start TKIs at lower than standard doses and titrate upward based on tolerability, as age and comorbidities increase blood pressure complications in this population. 4
• Avoid overhydration when using TKIs due to their large volume of distribution. 4
• Monitor heparin use during dialysis sessions to mitigate bleeding risk, as anemia is the most common adverse event with TKIs in dialysis patients. 4
• Blood pressure normalization at baseline and continuous monitoring during treatment is paramount, though control may be more challenging than in patients with better kidney function. 4

Immune Checkpoint Inhibitors

• No dose reduction is required for checkpoint inhibitors in dialysis patients, as there is no evidence supporting reduced treatment frequency based on lowered GFR or dialysis status. 4
• Autoimmune nephritis occurs in approximately 1% of patients (grade ≥3 toxicity) and typically reverses with drug discontinuation and steroid therapy. 4
• Checkpoint inhibitors can be restarted when prednisone dosing reaches ≤10 mg daily, though this recommendation lacks prospective study support. 4
• For steroid-refractory cases, consider mycophenolate mofetil or rituximab as alternative immunosuppressive options. 4

Erythropoietin-Stimulating Agents (ESAs)

• Target hemoglobin levels of 9.0–11.5 g/dL in dialysis patients with cancer, using nephrologic ESA dosing rather than oncologic dosing. 4
• While 2009 meta-analyses suggested ESAs increase mortality in cancer patients, a 2012 meta-analysis of 91 trials with >20,000 participants failed to show direct impact on cancer disease progression. 4
• No data exist on the likelihood of developing new cancers in dialysis patients during ESA therapy. 4

Common Pitfalls and How to Avoid Them

Premature Treatment Discontinuation

• In the CANDY study, chemotherapy was frequently omitted or prematurely stopped in dialysis patients despite clear indications for systemic treatment. 5
• This represents a critical error: dialysis status should not be considered a contraindication to chemotherapy but rather a need for individualized prescription according to available recommendations. 2

Inadequate Prescription Practices

• In the CANDY study, 72% of patients received at least one drug requiring dosage adjustment, and 82% received at least one drug requiring post-dialysis administration—yet these adjustments were frequently not made. 5
• Always verify both renal dosage adjustment requirements AND dialysability status before prescribing any anticancer agent. 1, 5

Overlooking Drug Accumulation

• Active catabolites of certain drugs can accumulate in hemodialysis patients, leading to unexpected severe adverse events. 4
• Published clinical recommendations regarding optimal timing and dose adjustment must be consulted for each specific anticancer drug. 4

Specific Clinical Scenarios

Renal Cell Carcinoma (RCC) in Dialysis Patients

• Dialysis patients are at increased risk for RCC due to acquired cystic kidney disease, chronic kidney disease itself, and prior nephrectomy. 4
• Treat metastatic RCC in dialysis patients with the same therapeutic intent as non-dialysis patients, using TKIs as first-line therapy with appropriate dose adjustments. 4
• Pazopanib, sunitinib, and tivozanib are all viable options with demonstrated efficacy in treatment-experienced patients. 4

Deciding Whether to Continue Dialysis During Cancer Treatment

• When cancer-related prognosis for survival is less than 2 weeks, dialysis should be stopped, as withdrawal from chronic dialysis leads to death within a few weeks. 4
• For patients with longer prognoses, dialysis can be framed as "palliative dialysis" focused on comfort and enabling participation in important life events rather than disease modification. 7
• Approximately 62% of patients who stopped dialysis accessed hospice, compared with only 16% who continued dialysis, reflecting systemic barriers rather than clinical appropriateness. 7

Quality Metrics and Outcomes

Patient-Centered Outcomes

• Replace disease-oriented ESRD quality metrics with patient-centered outcomes such as documented advance care planning, completion of advance directives, symptom assessment scores, and rates of out-of-hospital death. 7
• Standard ESRD Quality Incentive Program measures are inappropriate for seriously ill cancer patients with limited life expectancy. 7

Survival Data

• Survival in dialysis patients with incident cancer is poor overall, making appropriate treatment selection and supportive care even more critical. 5
• However, with proper dose adjustments and timing, comparable toxicity and effectiveness to standard dosing in patients with normal renal function can be achieved. 4

Practical Implementation Algorithm

1. Confirm cancer diagnosis and staging through standard oncologic evaluation
2. Assess kidney function using CKD-EPI equation (dialysis patients are functionally equivalent to CrCl <10-15 mL/min) 4
3. Convene multidisciplinary team (oncology, nephrology, pharmacy) before first treatment 1, 2, 3
4. For each proposed anticancer agent, determine:
   • Does it require renal dose adjustment? (57% do) 1
   • Is it dialyzable? (64% should be given post-dialysis) 1
   • What are the specific dosing recommendations for ESRD? 4
5. Schedule chemotherapy administration immediately after dialysis sessions for dialyzable drugs 1, 5
6. Monitor closely for adverse events, particularly cytopenia, diarrhea, and drug-specific toxicities 4
7. Reassess treatment plan regularly based on response, tolerance, and goals of care 7